Sio Gene Therapies Inc.
DelistedCIK 1636050fmd_19VAY00TVNBZVVACS2NSTA32VDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2014 to Dec 31, 2022, 32 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Realized investment gains (losses) | – | – | – | – | – | 11 | 0 |
| Research and development | 77 | 135 | 141 | 88 | 47 | 25 | 53 |
| Total operating expenses | 133 | 180 | 213 | 127 | 69 | 42 | 72 |
| Operating income | (133) | (182) | (221) | (129) | (72) | (33) | (72) |
| Interest expense | 0 | 1 | 8 | 8 | 4 | 1 | 0 |
| Other non-operating income (expense) | 0 | (0) | 0 | 6 | 1 | 10 | (0) |
| Income before taxes | (133) | (182) | (221) | (129) | (72) | (33) | (72) |
| Income tax expense | (0) | (1) | 1 | 0 | 0 | (0) | 0 |
| Net income from continuing operations | (133) | (181) | (222) | (129) | (73) | (32) | (72) |
| Net income | (133) | (181) | (222) | (129) | (73) | (32) | (72) |